By 2003, multiple research studies indicating that Risperdal might be dangerous for patients, especially children, began drawing negative attention to Janssen and its marketing practices. In response, parent company Johnson & Johnson published a paper entitled "Prolactin levels during long-term Risperidone treatment in children and adolescents." The paper stated ...

The evidence in the previous section clearly suggests that taking Risperdal can lead to serious side effects, particularly hyperprolactinemia and gynecomastia. However, can Janssen Pharmaceuticals (and parent company Johnson & Johnson) really be held responsible for these issues? Did they know about these risks when they promoted ...